NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · IEX Real-Time Price · USD
0.732
-0.029 (-3.76%)
At close: Jul 19, 2024, 4:00 PM
0.800
+0.068 (9.35%)
Pre-market: Jul 22, 2024, 8:00 AM EDT

NeuroSense Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Cash & Equivalents
2.642.643.5411.060.70.9
Short-Term Investments
003.55000
Cash & Cash Equivalents
2.642.647.0911.060.70.9
Cash Growth
-62.76%-62.76%-35.91%1482.69%-21.90%-
Receivables
0.240.240.260.310.030.02
Other Current Assets
0.040.040.040.040.040
Total Current Assets
2.922.927.3811.410.770.91
Property, Plant & Equipment
0.250.250.310.020.010.01
Other Long-Term Assets
0.020.020.02000.04
Total Long-Term Assets
0.270.270.340.020.010.04
Total Assets
3.193.197.7211.430.780.96
Accounts Payable
3.463.461.730.60.120.04
Total Current Liabilities
3.463.461.730.60.120.04
Long-Term Debt
0.070.070.15000
Other Long-Term Liabilities
1.411.4101.8300
Total Long-Term Liabilities
1.491.490.151.8300
Total Liabilities
4.944.941.872.430.120.04
Total Debt
0.070.070.15000
Debt Growth
-50.34%-50.34%----
Retained Earnings
-26.12-26.12-16.01-8.45-4.41-1.58
Shareholders' Equity
-1.76-1.765.849.010.660.92
Net Cash / Debt
2.572.576.9411.060.70.9
Net Cash / Debt Growth
-63.03%-63.03%-37.24%1482.69%-21.90%-
Net Cash Per Share
0.190.190.601.770.130.19
Working Capital
-0.54-0.545.6610.820.650.88
Book Value Per Share
-0.13-0.130.511.440.120.20
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).